Therapeutic efficacy and safety of joint application of Monosialotetra-hexosylganglioside Sodium and Vinpocetine in patients with acute cerebral infarction
- VernacularTitle:单唾液酸神经节苷脂联合长春西汀治疗急性脑梗死的临床疗效分析及安全性研究
- Author:
Shourong LU
;
Huizhu SONG
;
Yan CHEN
;
Xiaojun CAI
- Publication Type:Journal Article
- Keywords:
Monosialotetrahexosylganglioside Sodium;
Vinpocetin;
Cerebral infarction;
Neurologic function;
Safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(9):79-81
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate clinical therapeutic efficacy and safety of joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine in patients with acute cerebral infarction.Methods 60 patients with acute cerebral infarction, admitted to Wuxi People's Hospital Attached to Nanjing Medical University from January 2013 to July 2015, were randomly divided into observation group(n=30) and control group(n=30).They were both treated by identical basis therapy, such as antiplatelet, dilute blood viscosity, neurotrophy therapy and symptomatic treatment.The patients in the observation group were treated by joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine on the identical basis therapy.On the pretherapy and post-treatment day, the National Institutes of Health Stroke Scale (NIHSS), Barthel Index(BI), neuron specific enolase(NSE), hemodynamic indexes and efficiency of clinical treatment in these patients were performed.Blood routine examinations, hepatorenal function and ECG were monitored.CT SCan was employed for ICH and drug relative hemorrhage and adverse drug reaction( ADR) were recorded in detail.Results After treatment, 2 groups of NIHSS, BI score, blood rheology index, NSE level compared with before treatment improved significantly, the difference was significant (P<0.05).NSE, hemorheology and total effective rate of the observation group were better than the control group(P<0.05).The clinical total effective rate was 93.3% in treatment group and 76.6% in control group (P<0.05).During therapy period, There was no adverse reaction in 2 groups.Conclusion Joint application of Monosialotetrahexosylganglioside Sodium and the Vinpocetine is safe and effective in treating patients with acute cerebral infarction, through improving the clinical neurological deficits, blood rheology indicators and activity of daily living.
